Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery

January 05, 2015
Lung Cancer
Maria Quejada, MD

Naperville, Plainfield

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Sponsor: Alliance for Clinical Trials in Oncology

  • Clinical stage IB , II or IIIA non-squamous non-small cell lung cancer, completely resected
  • No patients who have received neoadjuvant therapy (chemo- or radio-therapy)
  • No interstitial fibrosis or lung disease
  • No prior or concurrent malignancies within 5 years, except non-melanoma skin carcinoma or in situ carcinomas
  • Adequate formalin-fixed, paraffin-embedded (FFPE) tissue available for central EGFR and ALK genotyping for all patients, including those already identified to carry eligible 
  • EGFR or ALK alterations

5-6 years

Accepting Participants
Kathy Seymour, BSN